Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Octreotide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    120 result(s) found for: Octreotide. Displaying page 3 of 6.
    « Previous 1  2  3  4  5  6  Next»
    EudraCT Number: 2021-000598-95 Sponsor Protocol Number: HS-20-674 Start Date*: 2021-07-30
    Sponsor Name:Camurus AB
    Full Title: A Phase 2, randomized, double-blind, placebo-controlled, multi-center trial to assess the efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with acute respiratory distress ...
    Medical condition: Acute respiratory distress syndrome (ARDS) caused by COVID-19 or other disorders
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001052 Acute respiratory distress syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-000507-12 Sponsor Protocol Number: RYZ101-301 Start Date*: 2023-06-12
    Sponsor Name:RayzeBio, Inc.
    Full Title: Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing...
    Medical condition: gastro-enteropancreatic neuroendocrine tumors (GEP-NETs)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001833-42 Sponsor Protocol Number: CRN00808-02 Start Date*: 2018-11-13
    Sponsor Name:Crinetics Pharmaceuticals, Inc.
    Full Title: A double-blind, placebo-controlled, randomized withdrawal study to evaluate the safety, pharmacokinetics and efficacy of CRN00808 in patients with acromegaly that are responders to octreotide LAR o...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) GR (Completed) PL (Completed) GB (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2011-006097-76 Sponsor Protocol Number: LOTUS Start Date*: 2013-01-11
    Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE "G. PASCALE"
    Full Title: RANDOMIZED PHASE 3 TRIAL EVALUATING THE EFFICACY OF LOCOREGIONAL TREATMENT WITH TRANSARTERIAL EMBOLIZATION (TAE) FOR LIVER METASTASIS, IN COMBINATION WITH OCTREOTIDE LAR, IN PATIENTS WITH NEUROENDO...
    Medical condition: PATIENTS WITH NEUROENDOCRINE TUMOR AND INOPERABLE LIVER METASTASIS
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002960-42 Sponsor Protocol Number: Yttrium-90-02 Start Date*: 2017-11-15
    Sponsor Name:AZIENDA UNITÀ SANITARIA LOCALE DELLA ROMAGNA
    Full Title: 173/5000 Forse cercavi: Terapia radiometabolica recettoriale-mediata con [90Y-DOTA0-Tyr3]-octreotide (90Y-DOTATOC) nei tumori endocrini del tratto gastroenteropancreatico e bronchiale. (Yttrium-90...
    Medical condition: Patients with Somatostatin receptors Neoplasms
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014713 Endocrine neoplasms malignant and unspecified HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-003963-58 Sponsor Protocol Number: 5FLUOCT Start Date*: 2005-03-07
    Sponsor Name:AZIENDA OSPEDALIERA S. LUIGI GONZAGA
    Full Title: CONTINOUS INFUSION OF 5-FLUORURACIL PLUS OCTREOTIDE LONG ACTING IN PATIENTS WITH NEUROENDOCRINE ADVANCED NOT SMALL CELL TUMORS
    Medical condition: TREATMENT OF PATIENTS WITH NON SMALL CELL NEUROENDOCRINE TUMORS WITH LOW PROLIFERATIVE ACTIVITY WITHOUT SURGICAL APPROACH
    Disease: Version SOC Term Classification Code Term Level
    10057270 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004033-32 Sponsor Protocol Number: RADIOMEN Start Date*: 2013-12-13
    Sponsor Name:FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
    Full Title: AN OPEN, MONOCENTRIC, NOT CONTROLLED CLINICAL TRIAL TO DEVELOP AND EVALUATE THE CLINICAL APPLICATION OF A NEW BETA PROBE FOR RADIOGUIDED SURGERY IN MENINGIOMA TUMOR
    Medical condition: SUBJECTS WITH CONVEXITY MENINGIOMA TUMORS OF NEW DIAGNOSIS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-005642-37 Sponsor Protocol Number: sandopouch-01 Start Date*: 2007-04-10
    Sponsor Name:University of Leuven, Division of Gastroenterology
    Full Title: Sandostatin® in the treatment of diarrhea in patients with ileal pouch anal anastomosis.
    Medical condition: IPAA Pouchitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005585-12 Sponsor Protocol Number: 1 Start Date*: 2007-12-20
    Sponsor Name:Department of Internal Medicine of the University of Munich
    Full Title: Prospektive, offene Studie zur Prüfung der Wirksamkeit der zusätzlichen Gabe des Somatostatinanalogon Octreotid (Sandostatin) bzw. des Dopaminagonisten Cabergolin (Dostinex) bei Patientin mit Akrom...
    Medical condition: acromegaly (= growth hormone hypersecretion mostly caused by a pituitary adenoma)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001078-94 Sponsor Protocol Number: 1981 Start Date*: 2007-05-21
    Sponsor Name:Radboud University medical centre
    Full Title: Treatment of dumping syndrome with Lanreotide Autogel
    Medical condition: treatment of the dumping syndrome with Lanreotide Autogel
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-000888-41 Sponsor Protocol Number: MetNET1trial Start Date*: 2014-06-05
    Sponsor Name:Fondazione IRCCS Istituto Nazionale dei tumori
    Full Title: Activity and safety of Everolimus in combination with octreotide LAR and Metformin in patients with advanced pancreatic well-differentiated Neuroendocrine Tumors (pWDNETs): a Phase II, open, mono...
    Medical condition: advanced/ or not resectable well differnciated pancreatic neuroendocrin tumor
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067518 Pancreatic neuroendocrine tumor LLT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068909 Pancreatic neuroendocrine tumour metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004179-11 Sponsor Protocol Number: 2018-4898 Start Date*: 2019-06-03
    Sponsor Name:Radboudumc
    Full Title: Effectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagic telangiectasia and symptomatic gastrointestinal bleeding, the SAIPAN-trial: a multicenter, randomized, open-label, pa...
    Medical condition: Hereditary hemorrhagic telangiectasia (HHT)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) DE (Ongoing) FR (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-023674-39 Sponsor Protocol Number: AKRO1 Start Date*: 2014-08-05
    Sponsor Name:Österreichisches Akromegalie Register
    Full Title: Evaluation of a standardized treatment regimen for acromegaly: A multi centre intervention study
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    17.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016722-13 Sponsor Protocol Number: CSOM230C2402 Start Date*: 2010-06-10
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase III, multicenter, randomized, parallel-group study to assess the efficacy and safety of double-blind pasireotide LAR 40 mg and pasireotide LAR 60 mg versus open-label octreotide LAR or lanr...
    Medical condition: Acromegaly is characterized by chronic hypersecretion of growth hormone (GH), clinical features comprise structural and functional changes occurring in practically all organs. Cardiovascular diseas...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) IT (Completed) NO (Completed) BE (Completed) DE (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-019066-92 Sponsor Protocol Number: 2-55-52030-730/TR321 Start Date*: 2010-08-31
    Sponsor Name:Ipsen Pharma SAS
    Full Title: A double-blind, randomized placebo-controlled clinical trial investigating the efficacy and safety of Somatuline Depot (lanreotide) Injection in the treatment of carcinoid syndrome
    Medical condition: Carcinoid syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10007270 Carcinoid syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LV (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-004507-18 Sponsor Protocol Number: CRAD001C2325 Start Date*: 2007-01-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, multicenter phase III study in patients with advanced carcinoid tumor receiving Sandostatin LAR® Depot and RAD001 10 mg/d or Sandostatin LAR® Depot a...
    Medical condition: Low grade neuroendocrine carcinoma consists of carcinoid and pancreatic endocrine tumors. These tumors originate from the neuroendocrine cells throughout the body and are capable of producing vario...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007276 Carcinoid tumour NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) FR (Completed) BE (Completed) SK (Completed) DE (Completed) ES (Completed) NL (Completed) GB (Completed) GR (Completed) IT (Completed) FI (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002630-31 Sponsor Protocol Number: CSOM230C2413 Start Date*: 2015-03-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase IIIb multicenter, open-label, single arm study to evaluate the efficacy and safety of pasireotide in patients with acromegaly inadequately controlled with first generation somatostatin ana...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    19.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) PT (Completed) IT (Completed) FR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-004707-12 Sponsor Protocol Number: CRAD001C2X01B Start Date*: 2013-05-16
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, multi-center everolimus roll-over protocol for patients who have completed a previous Novartis-sponsored everolimus study and are judged by the investigator to benefit from continued...
    Medical condition: Disease corresponding to the Novartis-sponsored study the patient will be transitioning from
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Prematurely Ended) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-005376-17 Sponsor Protocol Number: 201401 Start Date*: 2014-06-20
    Sponsor Name:Erasmus Medical Center
    Full Title: Sandostatin therapy in sarcoidosis
    Medical condition: Sarcoidosis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021428 - Immune system disorders 10003816 Autoimmune disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-003444-53 Sponsor Protocol Number: CSMS995BIT12 Start Date*: 2005-10-11
    Sponsor Name:NOVARTIS FARMA
    Full Title: A randomised, open label, multicenter study comparing the efficacy and safety of medical treatment with Sandostatin LAR 30 mg administered every 21 days for 6 months with that of Sandostatin LAR 60...
    Medical condition: Treatment of acromegalic patients partially responsive to somatostatin analogues
    Disease: Version SOC Term Classification Code Term Level
    6.1 10000599 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Feb 11 11:33:52 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA